Sarcoidosis remains an enigma in modern medicine. Its hallmark is the formation of noncaseating granulomas, primarily in the lungs, yet the disease extends ...

On Saturday, April 5, The Bernie Mac Foundation will hold its eighth annual Purple Carpet Fundraiser at the Orland Chateau in ...

Key findings • Sarcoidosis patients are prone to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, increased severity, morbidity and greater mortality of coronavirus disease 2019 ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage ...

aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows ...

Hiring Dalia Rayes as head of commercial for the global efzofitimod franchise slots another piece of the puzzle into place.

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A ...

Xentria's milestone advances XTMAB-16, a potential therapy for this inflammatory disorder with limited treatment options "This marks a significant step forward for the sarcoidosis community ...

“As we look to position efzofitimod as a potential chronic, maintenance therapy for patients with pulmonary sarcoidosis that can reduce or eliminate the use of oral corticosteroids, we are ...